Previous 10 | Next 10 |
home / stock / cmvlf / cmvlf news
Pfizer has been working on New Pfizer for almost a decade. The spin offs of Consumer Health and Upjohn appear to be the last steps. Continuation of the policy of dividend growth is a stated priority. Biopharma led by scientific pipeline innovation is expected to generate $15 ...
Cellectis S.A. (CLLS) Q3 2020 Earnings Conference Call November 6, 2020 8:00 AM ET Company Participants Simon Harnest – Senior Vice President, Corporate Strategy and Finance André Choulika – Chief Executive Officer Carrie Brownstein – Chief Medical Officer Eric Dutan...
Calyxt (CLXT) -13% premarket has entered into definitive agreements with institutional investors for the purchase and sale of 3.75M shares of shares, at a price of $4.00 per share, in a registered direct offering for gross proceeds of ~$15M.Cellectis S.A. (CMVLF), the Company’...
The following slide deck was published by Cellectis S.A. in conjunction with this Read more ...
BioMarin ( BMRN ) received a complete response letter or CRL for their hemophilia A gene therapy Valrox last week. As a result, the earliest commercial launch is now in 2023. Audentes ( ALPMF ) provided an update on their please 3 neuromuscular ASPIRO clinical trial indicating a third pati...
Cellectis S.A. (CLLS) Q2 2020 Earnings Conference Call August 06, 2020 7:30 AM ET Company Participants Simon Harnest - Vice President-Corporate Strategy & Finance André Choulika - Chairman & Chief Executive Officer Carrie Brownstein - Chief Medical Officer Eric Dut...
ObsEva Reports Positive Data from Phase 3 Uterine Fibroids Studies ObsEva SA ( OBSV ) announced positive top line data from its PRIMROSE 1 and 2 studies. PRIMROSE 1 met its primary endpoint at week 24 while PRIMROSE 2 data showed that continued treatment with linzagolix for 52 weeks offe...
Quick Take Nkarta ( NKTX ) intends to raise $150 million in an IPO of its common stock, according to an amended registration statement . The company is advancing a pipeline of drug candidates for the treatment of blood and other cancer indications. NKTX is still at preclinical stage of ...
Cellectis S.A. (CLLS) Q1 2020 Earnings Conference Call May 7, 2020 7:30 AM ET Company Participants Simon Harnest – Vice President-Corporate Strategy and Finance André Choulika – Chairman and Chief Executive Officer Carrie Brownstein – Chief Medical Offic...
Introduction Since my last article on Allogene Therapeutics ( ALLO ) about 5 months ago, its share price has fallen by around 30%, largely in part due to the stock market crash driven by the COVID-19 global pandemic . Despite the progress in clinical development, strong management tea...
News, Short Squeeze, Breakout and More Instantly...
Cellectis Romainville Ord Company Name:
CMVLF Stock Symbol:
OTCMKTS Market:
Cellectis Romainville Ord Website:
ALL represents 10% of all leukemia cases in the United States, progresses rapidly, and is typically fatal within weeks or months if left untreated 1 There is an urgent need to develop new therapies for ALL for patients who are not candidates for hematopoietic stem cell transpl...
NEW YORK, June 28, 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, held today a shareholders general meeting at 2:30 p.m. CET at the Biopark...
NEW YORK, June 20, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the publication of a...